Monitor the EHA 2026 poster presentation on June 13 for data quality and any partnership discussions. The clinical trial application timeline (H2 2026) is the next major catalyst. No immediate trading action warranted.
Price Chart
Executive Summary
Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 Congress in June. The data is preclinical and the company plans to submit a clinical trial application in H2 2026. This is a routine pipeline update with no financial data or near-term catalyst.
Key Facts
- Evaxion to present functional characterization data for EVX-04 at EHA 2026 Congress on June 13, 2026
- EVX-04 is an off-the-shelf therapeutic vaccine targeting acute myeloid leukemia (AML)
- Preclinical data shows EVX-04 prevents tumor growth in preclinical models
- Company plans to submit a clinical trial application in the second half of 2026
- No financial data, revenue, or guidance provided in the filing
Financial Impact
No financial impact disclosed; preclinical milestone with no revenue or cost figures
Risk Factors
- Preclinical data may not translate to clinical success
- Company requires additional capital to fund clinical development
- AML vaccine market is competitive with established therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003279 |
| Document: f6k_051226.htm | 0001171843-26-003279 |
| Document: 0001171843-26-003279-index-headers.html | 0001171843-26-003279 |
| Document: 0001171843-26-003279-index.html | 0001171843-26-003279 |
| Document: 0001171843-26-003279.txt | 0001171843-26-003279 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access